OncoMatch/Clinical Trials/NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
Is NCT06081920 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies IBI363 for melanoma.
Treatment: IBI363 — This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard treatment — first-line
Progression or recurrence after at least first-line systemic standard treatment
Lab requirements
Blood counts
hemoglobin <90 g/L; ANC <1.5 × 10^9/L; Platelet count <100 × 10^9/L
Kidney function
Serum creatinine >1.5 × ULN or CCr <45 mL/min (Cockcroft Fault formula, actual body weight)
Liver function
Total bilirubin >1.5 × ULN; AST or ALT >3 × ULN; If tumor liver metastasis, AST or ALT >5.0 × ULN
At baseline (within 7 days before the first administration of the study drug), there were any hematological abnormalities as follows: hemoglobin<90 g/L; Absolute neutrophil count (ANC)<1.5 × 10^9/L; Platelet count<100 × 10^9/L. At baseline (within 7 days prior to first administration), there were any serum biochemical abnormalities as follows: Total bilirubin>1.5 × ULN; AST or ALT>3 × ULN; If it is tumor liver metastasis, AST or ALT>5.0 × ULN; Serum creatinine>1.5 × ULN or CCr<45 mL/min, using the Cockcroft Fault formula to calculate CCr (using actual body weight); Albumin<30 g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06081920 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic standard treatment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages